In prostate cancer, several studies revealed that metformin mediates reduction in cell viability and arrest at the G1 phase of human prostate cancer cell lines, including DU145, PC3, LNCaP, 22Rv1, C4-2 and also canine prostate cancer cells [49,51,52,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80], without showing evidence of an effect on normal cells (such as RWPE, PREC or P69) [52,66,77]. Here, ICA1 is linked to prostate carcinoma.